# US 2013/0156803 A1 · Compositions and methods related to p6

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156803 A1
- Document ID: US20130156803A1
- Status: Published application
- Kind: A1
- Application number: 13/488,251
- Filed: 2012-06-04
- Published: 2013-06-20
- Earliest claimed: 2011-06-04
- Assignees: Rochester General Hospital Research Institute
- Inventors: MICHAEL PICHICHERO; M. NADEEM KHAN; RAVINDER KAUR; SHARAD SHARMA; JANET CASEY; LEA MICHEL
- Web page: https://patentgrep.com/patent/US20130156803A1

## CPC

- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM.

## Claims

### Claim 1

An epitope for an immunization against Nontypeable Haemophilus influenzae (NTHi), selected from the group of peptides of 3B9, 7F3 and 4G4, or mixtures thereof.

### Claim 2 (depends on 1)

The epitope of claim 1, reactive with anti-P6 polyclonal antibodies.

### Claim 3 (depends on 2)

The epitopes of claim 2, in combination with a pharmaceutical carrier for administration to a subject.

### Claim 4 (depends on 3)

The epitopes of claim 3, in an effective concentration for administration to a subject to neutralize Nontypeable Haemophilus influenzae (NTHi).

### Claim 5 (depends on 1)

The epitopes of claim 1, further comprising a pharmaceutical carrier for administration to a patient, wherein the carrier and concentration of sequences elicit an immune response when administered to a subject.

### Claim 6 (depends on 1)

The epitopes of claim 1 labeled with a compound selected from the group consisting of dyes, fluorescent labels, chemiluminescent labels, enzymes, and radioactive labels.

### Claim 7 (depends on 1)

The epitopes of claim 1 immobilized onto a substrate.

### Claim 8 (depends on 1)

A method for screening patients for Nontypeable Haemophilus influenzae (NTHi) infection comprising reacting a biological sample with the epitopes of claim 1.

### Claim 9 (depends on 8)

The method of claim 8 wherein the epitopes are labeled with a compound selected from the group consisting of dyes, fluorescent labels, chemiluminescent labels, enzymes, and radioactive labels.

### Claim 10 (depends on 8)

The method of claim 8 wherein the epitopes are immobilized onto a substrate.

### Claim 11 (depends on 10)

The method of claim 10, further comprising predicting the prognosis of the patient based on the reactivity of the patient sample with the epitopes.

### Claim 12 (depends on 1)

A method for treating patients for Nontypeable Haemophilus influenzae (NTHi) comprising administering to the patient an epitope of claim 1, or mixtures thereof, in an amount effective to inhibit a Nontypeable Haemophilus influenzae (NTHi) infection.

### Claim 13 (depends on 12)

The method of claim 12 wherein the epitope acts as a vaccine against Nontypeable Haemophilus influenzae (NTHi) infection.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject has an Nontypeable Haemophilus influenzae (NTHi) ear infection.

### Claim 15 (depends on 12)

The method of claim 12, wherein the subject is prone to ear infections.

### Claim 16 (depends on 1)

A vaccine for inhibiting infection comprising the epitope of claim 1, in combination with an antigenic pharmaceutical carrier.

### Claim 17 (depends on 1)

A method for vaccinating a host against a Nontypeable Haemophilus influenzae (NTHi) infection comprising providing the epitope of claim 1 in combination with an antigenic pharmaceutical carrier.

### Claim 18 (depends on 1)

The epitope of claim 1, wherein the epitope is at a concentration of at least 1.1, 1.2, 1.3, 1.5, 1.7, 1.9, 2.0, 2.5, 3.0, 5, 7, or 10 fold the P6 and P6 epitope of a vaccine having P6, protein D, and OMP24 present in them.

### Claim 19 (depends on 18)

A vaccine comprising the epitope of claim 18.

### Claim 20 (depends on 19)

The vaccine of claim 19, further comprising P6 at a concentration of at least 1.1, 1.2, 1.3, 1.5, 1.7, 1.9, 2.0, 2.5, 3.0, 5, 7, or 10 fold the P6 and P6 epitope of a vaccine having P6, protein D, and OMP24 present in them.

### Claim 21

A vaccine comprising P6 at a concentration of at least 1.1, 1.2, 1.3, 1.5, 1.7, 1.9, 2.0, 2.5, 3.0, 5, 7, or 10 fold the P6 and P6 epitope of a vaccine having P6, protein D, and OMP24 present in them.

### Claim 22 (depends on 18)

A vaccine further comprising the epitope of claim 18.

### Claim 23 (depends on 1)

A vaccine comprising P6, or an epitope of claim 1, or mixture there of, wherein the vaccine comprises a concentration of antigen greater than 1.1, 1.2, 1.3, 1.5, 1.7, 1.9, 2.0, 2.5, 3.0, 5, 7, or 10 fold the P6 and P6 epitope antigen of a vaccine having P6, protein D, and OMP24 present in them.

### Claim 24 (depends on 8)

The vaccine as claimed in claim 8, wherein the vaccine is in a capsular form.

### Claim 25 (depends on 23)

A method of vaccination, said method comprising step of administering therapeutically effective dose of the vaccine of claim 23 to a subject in need thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the subject has Nontypeable Haemophilus influenzae (NTHi).

### Claim 27 (depends on 25)

The method of claim 25, wherein the subject is prone to have Nontypeable Haemophilus influenzae (NTHi).

### Claim 28 (depends on 25)

The method of claim 25, wherein the vaccine is administered through an oral route or intra peritoneal route.

### Claim 29 (depends on 25)

The method of claim 25, wherein the vaccine is administered in capsular form.

### Claim 30 (depends on 25)

The method of claim 25, wherein the vaccine is administered at a dosage ranging from 0.01 mg/ml/kg to 100 mg/ml/kg.

### Claim 31 (depends on 25)

The method of claim 25, wherein the vaccine is capable of inhibiting an Nontypeable Haemophilus influenzae (NTHi) infection in a subject prone to Nontypeable Haemophilus influenzae (NTHi), to a greater extent than a vaccine comprising Protein D or OMP26.

### Claim 32 (depends on 22)

A kit for vaccination, said kit comprising a vaccine of claim 22 in a deliverable form.

### Claim 33

A vaccine comprising P6 and Protein D, epitopes of P6 or Protein D, or mixtures thereof, but not OMP26 of non typeable Haemophilus influenzae (NTHi).

### Claim 34 (depends on 33)

The vaccine of claim 33, wherein the vaccine consists of P6 or P6 epitopes.

### Claim 35 (depends on 34)

A method of treating a child, comprising identifying a child wherein the child is prone to having acute otitis media (AOM) and administering the vaccine of claim 34 to the child.
